Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.
Age ≥ 18 years.
Diagnosis of B-cell ALL.
Detection of new MRD positivity after prior MRD negativity, or frank relapse while receiving or after blinatumomab. MRD positivity will be assessed by multiparameter flow
You may not be if
Loss of CD19 expressions.
Participants with active CNS 3 disease (central nervous system leukemia involvement)
Uncontrolled infection
Philadelphia positive disease (9;22 translocation at location of BCR-ABL1 fusion)